Three-year outcomes of cystotomy and fibrinogen clot removal for diabetic macular edema with subfoveal cystoid macular edema

糖尿病性黄斑水肿伴中心凹下囊样黄斑水肿患者行囊切开术和纤维蛋白原凝块清除术三年疗效

阅读:1

Abstract

Several new surgical techniques for managing refractory diabetic macular edema (DME) have demonstrated favorable short-term outcomes. However, no studies have reported the long-term outcomes of these treatments. This study aimed to evaluate the long-term outcomes of cystotomy for DME retrospectively. Twenty-seven patients (31 eyes; 16 male, 11 female) who underwent cystotomy for DME between January 2015 and April 2019, with a follow-up period of 3 years were included. Statistical analyses involved variables including age, sex, best-corrected visual acuity (BCVA), central macular thickness (CMT), number of treatments (anti-vascular endothelial growth factor, sub-Tenon injection of triamcinolone acetonide, direct photocoagulation for microaneurysms, vitrectomy with internal limiting membrane peeling), number of clinic visits, and DME recurrence. The mean age was 67.2 ± 9.3 years. BCVA (logMAR) and CMT(µm) significantly improved from preoperatively to 3 years postoperatively (P < 0.001). Total treatments significantly decreased from the year before surgery to the third year after surgery (P < 0.001). The mean number of clinic visits significantly decreased from the year before surgery to the third year after surgery (P < 0.001). Fibrinogen clot removal was performed in 14 eyes. and DME recurrence occurred in 12 eyes. Cystotomy may be a viable treatment option for DME.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。